HealthQuill
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
The World Health Organization has unveiled a '3 by 35 initiative,’ urging governments to impose a health tax of about 50% on alcohol, sugary drinks and tobacco that are fuelling a noncommunicable disease (NCD) epidemic globally.
Drugs Health Pharma

Slap 50% tax on alcohol, sugary drinks, tobacco to curb NCDs: WHO

HQ Team July 3, 2025: The World Health Organization has unveiled a ‘3 by 35 initiative,’ urging governments to impose a health tax.

Read More
Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.
Drugs Health Pharma

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

Read More
Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after it failed to meet its main efficacy goal.
Drugs Health Pharma

Organon halts endometriosis drug trial as it fails to meet efficacy goal

HQ Team July 2, 2025: Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after.

Read More
Drugs Health Medical

One child killed or maimed every 15 minutes in Middle East, North Africa

HQ Team July 2, 2025: In less than two years, one child has been killed or maimed every 15 minutes in conflicts across.

Read More
A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making it difficult to use the results in practice, according to researchers from the University of Copenhagen and the University of São Paulo.
Drugs Health Research

Researchers find serious flaws in clinical trials with adult ADHD patients

HQ Team July 2, 2025: A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making.

Read More
The European Commission has approved Vertex Pharmaceuticals' drug to treat cystic fibrosis in adults and children above six years of age who have certain genetic mutations related to the disease.
Drugs Health Pharma

EC approves Vertex’s once-daily drug combination to treat cystic fibrosis 

HQ Team July 3, 2025:  The European Commission has approved Vertex Pharmaceuticals‘ drug to treat cystic fibrosis in adults and children above six.

Read More
Medical experts at Cincinnati Children’s have made an organoid, or ‘organs in a dish,’ of human lung tissue that produces its own blood vessels, according to a statement.
Drugs Health Research

Cincinnati team’s lab-made lung tissue produces its own blood vessels

HQ Team July 1, 2025: Medical experts at Cincinnati Children’s have made an organoid, or ‘organs in a dish,’ of human lung tissue.

Read More
Amgen Inc.’s drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer compared to chemotherapy alone, according to a company statement.
Drugs Health Pharma

Amgen’s trial drug for gastric cancer patients helps them live longer

HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.

Read More
AbbVie Inc. will buy Capstan Therapeutics, Inc., a clinical-stage biotechnology company, for $2.1 billion in cash to acquire the latter’s investigational medicine to treat autoimmune diseases and its delivery technology.
Uncategorized

AbbVie to acquire Capstan for $2.1b, gets experimental drug, technology 

HQ Team June 30, 2025: AbbVie Inc. will buy Capstan Therapeutics, Inc., a clinical-stage biotechnology company, for $2.1 billion in cash to acquire.

Read More